Takeda Pharmaceutical Company Limited (TAK) は上場企業です ヘルスケア セクターの Drug Manufacturers - Specialty & Generic 業界で事業展開. 本社所在地は Tokyo, 日本. 現CEOは Christophe Weber.
TAK を有する IPO日 2010-01-05, 49,281 名の正社員, に上場 NYSE, 時価総額 $56.39B.
Takeda Pharmaceutical Company Limited is a globally diversified pharmaceutical company headquartered in Tokyo, Japan, with operations across North America, Europe, Latin America, Russia, and Asia. Founded in 1781, Takeda engages in the research, development, manufacturing, and commercialization of pharmaceutical products across key therapeutic areas including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience. The company markets numerous branded products such as Entyvio, Velcade, Adcetris, and Trintellix, and maintains an extensive portfolio of strategic collaborations and licensing agreements with leading biotech firms and research institutions to support its pipeline development and innovation initiatives.
